A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals (UK) Limited · NCT07096674
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–65 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 2
- Target enrollment
- 90
- US sites recruiting
- 19
- Study start
- August 12, 2025
- Record last updated
- April 16, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).
Being studied: ORX750; ORX750; ORX750
Conditions: Narcolepsy Type 1; Narcolepsy Type 2; Idiopathic Hypersomnia
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
- Is willing and able to adhere to additional protocol requirements
Exclusion Criteria
- Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study
- Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia
Recruiting US locations
Auburn, alabama
Auburn, AL 36832
Santa Ana, California
Santa Ana, CA 92705
Miami, Florida
Miami, FL 33176
Orlando, Florida
Orlando, FL 32807
Winter Park, FL
Winter Park, FL 32789
Stockbridge, GA
Atlanta, GA 30281
Atlanta, Georgia
Atlanta, GA 30328
Sterling Heights, Michigan
Sterling Heights, MI 48314
Hendersen, Navada
Henderson, NV 89052
Henderson, Nevada
Henderson, NV 89052
Denver, North Carolina
Denver, NC 28037
Huntersville, North Carolina
Huntersville, NC 28070
Cincinnati, Ohio
Cincinnati, OH 45245
Dublin
Dublin, OH 43017
Abington, Pennsylvania
Abington, PA 19046
Willow Grove, Pennsylvania
Willow Grove, PA 19090
North Charleston, South Carolina
North Charleston, SC 29406-9196
Austin, Texas
Austin, TX 30328
El Paso, Texas
El Paso, TX 79912
Study contacts (from the official record)
- Orexin Centessa Program Lead · 617-468-5770 · ORX750-LTE@centessa.com
Similar studies in Alabama
All sleep studies in Alabama →- RecruitingPhase 2/Phase 3
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc.
- Location
- Cullman, AL + 32 other US sites
- Eligibility basics
- Ages 18–70
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly and Company
- Location
- Cullman, AL + 22 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH
Jazz Pharmaceuticals
- Location
- Birmingham, AL + 14 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
Alkermes, Inc.
- Location
- Cullman, AL + 21 other US sites
- Eligibility basics
- Ages 18–70